Vivani Medical Inc. (NASDAQ:VANI) expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024. The NPM-115 clinical program will evaluate the ...
The company does not expect a material change in revenues before receiving FDA marketing authorization for ProSense in early-stage breast cancer. Shamir stated, "As we wait the FDA decision, we also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results